Filing Details

Accession Number:
0000950170-24-002111
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-04 18:24:01
Reporting Period:
2024-01-02
Accepted Time:
2024-01-04 18:24:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178879 Amicus Therapeutics Inc. FOLD Pharmaceutical Preparations (2834) 200422823
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1666380 Ellen Rosenberg 47 Hulfish Street
Princeton NJ 08542
Chief Legal Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-02 30,000 $5.16 372,285 No 4 M Direct
Common Stock Disposition 2024-01-02 30,000 $14.21 342,285 No 4 S Direct
Common Stock Acquisiton 2024-01-02 63,131 $0.00 405,416 No 4 A Direct
Common Stock Disposition 2024-01-02 6,985 $14.24 398,431 No 4 F Direct
Common Stock Disposition 2024-01-03 15,397 $13.53 383,034 No 4 F Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 A Direct
No 4 F Direct
No 4 F Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (right to buy) Disposition 2024-01-02 30,000 $0.00 30,000 $5.16
Common Stock Stock Options (right to buy) Acquisiton 2024-01-02 108,980 $0.00 108,980 $14.24
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
30,000 2026-02-08 No 4 M Direct
108,980 2034-01-02 No 4 A Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 15,000 Indirect By Spouse
Footnotes
  1. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.00 to $14.35 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in four equal annual installments beginning on January 2, 2025 and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.
  3. All of the options were fully vested and exercisable as of the transaction date.
  4. These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.